




Mass Gathering Risk Assessment: Hajj 1445H (2024)


Developed internally by Gulf CDC Public Health Emergency Department on 5 June 2024

I. Background of the Mass Gathering

(a) Overview

Hajj is the annual religious ritual gathering of Muslims that takes place in Makkah, Saudi Arabia, and it is one of the largest annual mass gatherings in the world. Every year, more than one million people perform Hajj. Historically, the number of pilgrims reached nearly 3 million in some years; however, last year, 1444/2023, the number of pilgrims surged to 1,845,045, a significant increase from the number of pilgrims in the previous year, 1443/2022, 926,062 due to COVID-19 restrictions ⁽¹⁾⁽²⁾. The historical travel origin of the pilgrims is described in Figures 1 and 2.





Hajj is a mass gathering that has a high possibility of spreading infectious diseases and requiring public health monitoring. The risk of infectious disease transmission during Hajj may extend to the local population, other GCC countries, and the home population of returning pilgrims after Hajj. There are several public health risks increased in mass gatherings such as Hajj, including heat-related illnesses and the risk of transmission of respiratory diseases, food and water-borne diseases, and meningococcal diseases ⁽³⁾⁽⁴⁾⁽⁵⁾. Some large infectious disease outbreaks that previously occurred during Hajj were:

- Meningococcal disease: In 1987, serogroup A caused an outbreak, while serogroup W135 was responsible for outbreaks in 2000 and 2001 ⁽⁶⁾.
- Cholera: In 1821, an estimated 20,000 pilgrims died during the Hajj due to a cholera epidemic, which started in India in 1817 and spread across the world. Similarly, in





1865, an estimated 15,000 out of 90,000 pilgrims died due to the cholera epidemic that spread throughout the world ⁽⁷⁾.

Other public health hazards have been documented in the past, such as heat-related illnesses, stampedes, and suffocation. In Hajj season 1997/1417, a fire occurred in Mina tents, which led to the death of 343 people and the injury of more than 1,500 people as a result of a gas cylinder explosion ⁽⁸⁾.

Therefore, a risk assessment of prevailing priority hazards would support identifying appropriate public health precautions to be considered by health authorities in GCC countries to prevent or reduce the potential emergencies that could occur in the region as a result of Hajj.

(b) Potential Hazards

There are several hazards to be considered in preparation for the upcoming Hajj pilgrimage in 2024. These include:

- Infectious diseases with a risk of immediate transmission (e.g. COVID-19, measles, etc).
- Infectious diseases that can have high consequences but are typically reported sporadically (i.e. MERS, anthrax, meningococcal disease, avian influenza, Crimean Congo hemorrhagic fever, ebola, botulism, kyasanur forest disease, marburg virus disease).
- Infectious diseases that do not present as an immediate transmission risk during the Hajj but have a risk of long-term establishment in Saudi Arabia due to the presence of a competent vector (i.e., chikungunya, malaria, yellow fever, zika, dengue) as well as the potential of introducing or importing a new vector to the Hajj region.
- Injuries due to stampedes caused by overcrowding.
- Heat-related illnesses include heat stroke and exhaustion due to prolonged outdoor exposure to high temperatures.
- Fires due to accidental events (such as gas canister explosions).
- Food-borne and water-borne diseases/outbreaks.
- Complications from non-communicable diseases.

The Gulf CDC has reviewed the potential hazards and prioritized the assessment of infectious disease transmission (first three hazards listed above) as a focus for this report.





II. Risk Assessment

(a) Risk Question

What is the risk of infectious disease <u>transmission occurring in the GCC in the next 3 months</u> as a result of the 2024 Hajj based on the diseases with the highest chance of importation or exportation during/after Hajj?

(b) Likelihood & Impact

Diseases with the highest importation or exportation (Importation likelihood refers to the chance of one case of the disease being imported to Saudi Arabia within the Hajj period, around 30 days and Exportation likelihood refers to the chance of one case of the disease being exported from Saudi Arabia as a result of the Hajj) have been identified based on the epidemiological situation in the top 10 countries where the highest number of pilgrims would come from in 2024 (see Appendix A for importation likelihood) and based on the national priorities set by the Ministry of Health of Saudi Arabia ⁽⁹⁾.





Note: Risk has been calculated based on the levels of **likelihood** and **impact** of the transmission across the GCC countries (see **Appendix B** for the **risk matrix**) and the **Risk Level** is shown for the identified diseases in the tables below. Details of the analyses conducted to allocate the levels of **likelihood** and **impact** are documented in a separate internal report (available upon request), and only high-level assessment outcomes disease-by-disease are summarized below.

| COVID-19 | | | | | | | | |
|--|---|---------------------|--------------------|-------------------|-----------------------|--|--|--|
| Negligible | Very Low | Low | Moderate | High | Critical | | | |
| Gulf CDC Risk A | ssessment of thi | is Hazard | - | | | | | |
| COVID-19 is an | infectious diseas | se caused by the S | ARS-CoV-2 virus | . Most individua | ls infected with | | | |
| the virus will ex | perience mild to | moderate respira | atory illness and | recover without | needing special | | | |
| treatment. The | likelihood of an | increased numbe | r of COVID-19 ca | ses due to impo | rtation by | | | |
| incoming pilgrir | ms is 0.711 from | India, 0.163 from | Bangladesh, and | 0.100 from Pal | kistan. | | | |
| Additionally, ne | ew FLiRT COVID v | variants have beer | n reported in ma | ny countries in t | he world, | | | |
| including India. | The term "FLiRT | " encompasses a | range of variants | , including KP.2 | , JN.1.7 <i>,</i> and | | | |
| other variants s | starting with KP of | or JN, that have in | dependently acq | uired similar m | utations. | | | |
| Vaccines target | ing JN.1 produce | e some cross-reac | tive antibodies. T | he recent conce | erns about the | | | |
| FLiRT subvarian | ts circulating glo | bally and reports | of increased hos | pitalizations ass | ociated with | | | |
| these variants o | could elevate the | e risk; however, th | e focus of this re | port is on the to | op 10 countries | | | |
| of pilgrim origin | ns. The Saudi Mii | nistry of Health ha | as recommended | that all pilgrims | aged 12 and | | | |
| | | rims from Saudi A | • | • | | | | |
| mandatory ⁽¹¹⁾ . | mandatory ⁽¹¹⁾ . Health education was provided to the community about the COVID-19 disease and | | | | | | | |
| preventive measures across the GCC countries; several pilgrims may opt to use masks during | | | | | | | | |
| pilgrimage to re | educe personal r | isk and the vaccin | ation coverage for | or COVID-19 is h | igh in the GCC | | | |
| countries. | | | | | | | | |

| Influenza | | | | | | | | | |
|---|---------------------|-------------------|-------------------|--------------------------------|------------------|--|--|--|--|
| Negligible | Very Low | Low | Moderate | High | Critical | | | | |
| Gulf CDC Risk As | ssessment of this | Hazard | | | | | | | |
| Individuals infe | cted with influe | nza frequently e | experience an im- | mediate onset o | of cough, fever, | | | | |
| headache, and | myalgia. Influenz | a has a high like | lihood of spreadi | ng due to its res | piratory nature | | | | |
| and some pract | ices during Hajj t | hat could enable | its transmission | ⁽¹²⁾ . However, the | e Saudi Ministry | | | | |
| of Health has ac | dvised that all ext | ernal pilgrims re | ceive vaccination | and has mandat | ed vaccinations | | | | |
| for internal pilgrims. Oman health authorities have also mandated the vaccination for pilgrims. | | | | | | | | | |
| Additionally, constant and active vaccination campaigns that raise awareness and promote | | | | | | | | | |
| influenza preve | ntion have been | conducted acros | s GCC countries. | | | | | | |





| Measles | | | | | |
|------------------------------|----------------------|---------------------------------|---------------------|--------------------|-------------------|
| Negligible | Very Low | Low | Moderate | High | Critical |
| Gulf CDC Risk A | ssessment of this | s Hazard | | | |
| Measles is a se | vere disease caus | sed by a virus. It s | spreads easily wh | nen an infected p | erson breathes, |
| coughs or snee | zes. Measles has | an incubation p | eriod of 10-12 d | ays. Based on the | e current global |
| epidemiologica | I situation due to | increasing vaccin | ation hesitancy, r | neasles can be im | ported through |
| Hajj from multi | iple countries and | d spread as pilgri | ms return to the | ir home countrie | s after the Hajj. |
| Current estima | tes suggest that | the likelihood of | a measles case l | being imported d | luring Hajj from |
| Pakistan (0.820 |) is the highest, fo | ollowed by Iraq (0 | .652), Nigeria (0.: | 144), and India (0 | .070). However, |
| pilgrims are no | ot considered a h | igh-risk group fo | r measles, as th | e primary at-risk | individuals are |
| children and th | e unvaccinated p | opulation ⁽¹³⁾ . The | e Saudi Ministry o | of Health has reco | ommended that |
| all pilgrims ha | ve completed th | ne required vacc | inations in their | national vaccin | ation schedule, |
| including vacci | nation against di | phtheria, tetanus | , pertussis, polio | , measles, varice | lla, and mumps |
| ⁽¹¹⁾ . The GCC co | untries have high | vaccination cove | erage against me | asles in 2022 with | n high detection |
| and response c | apacities for mea | sles; this would o | contribute to ear | ly detection and | management of |
| any increased in | mportation of Me | easles cases. | | | |

| Dengue | | | | | | | | |
|-------------------|---|----------------------|---------------------|---------------------|--------------------|--|--|--|
| Negligible | Very Low | Low | Moderate | High | Critical | | | |
| Gulf CDC Risk A | ssessment of this | s Hazard | | | | | | |
| Dengue is a veo | ctor-borne diseas | se that can be im | ported during Ha | ijj. The likelihood | l of one dengue | | | |
| case being impo | orted during Hajj | is estimated to be | 0.999 from Indoi | nesia, 0.948 from | Pakistan, 0.876 | | | |
| from India, and | 0.351 from Bang | gladesh. It is almo | st certain for sev | eral cases to be i | mported during | | | |
| the Hajj period | . However, the s | urveillance and c | ase management | capacities of GC | C countries are | | | |
| high enough to | detect and treat | these imported c | ases early, meritir | ng a "low" impact | t on case fatality | | | |
| rates. In additio | on, although auto | chthonous transr | nission has alread | dy been establish | ed in some GCC | | | |
| countries as we | ell as the import | ation of cases th | roughout the yea | ar from global ar | nd neighbouring | | | |
| countries, the H | lajj mass gatherii | ng itself might no | t have a bigger ef | fect on Dengue i | mportation into | | | |
| the GCC. Howe | the GCC. However, there remains a chance of local transmission due to the presence of competent | | | | | | | |
| vectors in sever | ral GCC countries | . The possible ext | ent of this transm | nission is current | ly unknown due | | | |
| to information | unavailability, a | nd it is difficult t | o determine out | break risk with | limited data on | | | |
| vector/s. | | | | | | | | |





| Mumps | | | | | | | | |
|---|---|--------------------|----------------------|----------------------|------------------|--|--|--|
| Negligible | Very Low | Low | Moderate | High | Critical | | | |
| Gulf CDC Risk A | ssessment of this | s Hazard | | | | | | |
| Mumps is a co | ntagious viral dis | sease that typica | lly presents with | initial symptom: | s such as fever, | | | |
| headache, mus | cle aches, fatigue | e, and loss of app | petite over a few | days. The incuba | ation period for | | | |
| mumps ranges f | from 16 to 18 day | s, and the disease | e may spread whe | n pilgrims return | to their country | | | |
| after performir | ng the Hajj. Base | d on estimates f | rom the top ten | countries of pil | grim origin, the | | | |
| likelihood of on | e case being impo | orted to Saudi Ara | abia is only from li | ndia and is projec | ted to be 0.829. | | | |
| The severity of | f mumps is low, | as serious comp | lications are rare | e. The Saudi Mir | nistry of Health | | | |
| advised that all | pilgrims should | be vaccinated ag | ainst mumps as p | part of their nation | onal vaccination | | | |
| schedule ⁽¹¹⁾ . M | schedule ⁽¹¹⁾ . Mumps risks spreading to those who are unvaccinated or not fully vaccinated due to | | | | | | | |
| missed vaccine schedules following the COVID-19 pandemic. In the GCC countries, vaccination | | | | | | | | |
| coverage again | st mumps in 20 | 22 is high, and t | the countries ha | ve the capability | / to detect and | | | |
| respond to mur | nps and will be a | ble to manage ar | ny new imported | cases. | | | | |

| Malaria | | | | | | | | | | |
|--|---|---|---|---|---|--|--|--|--|--|
| Negligible | Very Low | Low | Moderate | High | Critical | | | | | |
| Gulf CDC Risk A | ssessment of this | Hazard | | | | | | | | |
| malaria case be 0.311 from Ind however, mala impact if an o transmission, is | ctor-borne diseas eing imported du ia. There is a wic ria poses a low r putbreak occurs, s "Unlikely". Stro page any imported | ring Hajj is estim lespread distribu isk to the GCC p the likelihood ng public health | nated to be one tion of malaria v opulation, despi of introduction, measures and ex | from Indonesia a ectors in several te the potential either through kisting capacities | and Nigeria and I Gulf countries; for "moderate" travel or local | | | | | |

| Meningococcal disease | | | | | | | | | | |
|-----------------------|--|-------------------|-------------------|-----------------------|---------------------------|--|--|--|--|--|
| Negligible | Very Low | Low | Moderate | High | Critical | | | | | |
| Gulf CDC Risk Ass | Gulf CDC Risk Assessment of this Hazard | | | | | | | | | |
| Meningococcal d | isease is a severe | disease caused | by the bacteriur | m <i>Neisseria me</i> | <i>ningitides</i> . It is | | | | | |
| | within 24 hours of | | | | | | | | | |
| | a history of trave | | | | - | | | | | |
| | ance, three from | • | | | | | | | | |
| • | that pilgrims will l | • | • • | | | | | | | |
| | ood of importing | • | | • | | | | | | |
| • | ernal) and season | | | | | | | | | |
| | red to have a valio | | • | | | | | | | |
| • | dividuals carrying | | | • | | | | | | |
| • | f is not provided. | | • | | | | | | | |
| | lgrims from cour | | • | • | • | | | | | |
| | countries at risk of meningitis epidemics if deemed necessary (10)(11) (see Appendix C). Most of the | | | | | | | | | |
| | ve meningococca | | | | | | | | | |
| | ic health systems | and infrastructur | re that can detec | t and respond t | o outbreaks of | | | | | |
| meningococcal di | sease | | | | | | | | | |





| Cholera | | | | | | |
|---|---------------------|---------------------|----------------------------------|---------------------|-------------|--|
| Negligible | Very Low | Low | Moderate | High | Critical | |
| Gulf CDC Risk A | ssessment of this | s Hazard | | | | |
| Cholera is a bac | terial disease that | at causes severe o | diarrhoea and del | hydration. There | has been an | |
| increasing num | ber of cholera ou | tbreaks globally, | increasing the lik | elihood of infect | ed pilgrims | |
| arriving from co | ountries with ong | oing cholera out | breaks. The curre | nt ongoing seven | ith global | |
| cholera panden | nic is caused by t | he bacterium Vib | orio cholerae, with | n El-Tor strain (se | rogroup O1) | |
| being one of th | e dominant straiı | ns and considered | d hemolytic ⁽¹⁴⁾ . Ba | ased on estimate | s, the | |
| likelihood of ch | olera one case be | eing imported du | ring Hajj is 0.798 | from Pakistan, 0. | 740 from | |
| Bangladesh, 0.4 | 187 from Turkey, | and 0.084 from I | ndia and could be | e considered as " | unlikely". | |
| Strong WASH infrastructure and high healthcare capacity in the GCC will effectively prevent local | | | | | | |
| transmission. T | he overall impact | c of a potential οι | utbreak is expecte | ed to be "modera | te" due to | |
| these existing n | nitigation measu | res. | | | | |

| Crimean-Congo | Crimean-Congo Hemorrhagic Fever (CCHF) | | | | | | | | | | |
|--|--|--------------------|-------------------------------|--------------------|----------------------------|--|--|--|--|--|--|
| Negligible | Very Low | Low | Moderate | High | Critical | | | | | | |
| Gulf CDC Risk As | ssessment of this | Hazard | | | | | | | | | |
| Crimean-Congo | Hemorrhagic Fev | /er is a widesprea | d disease caused | by a tick-borne v | irus (<i>Nairovirus</i>) | | | | | | |
| | | | n increasing in a n | | | | | | | | |
| | - | | ported. ⁽¹⁵⁾ . CCH | • | | | | | | | |
| population, as t | he likelihood of c | outbreaks is consi | dered "likely" du | e to Eid Al-Adha d | occurring during | | | | | | |
| | | • | ential peak in vir | | | | | | | | |
| tick activity. Ho | wever, the impa | ct is considered | "moderate" due | to existing robu | st public health | | | | | | |
| measures like case surveillance, isolation protocols, potential implementation of travel and | | | | | | | | | | | |
| livestock screen | ing programs fro | m high-risk regio | ns, and awarenes | ss campaigns hel | d around Eid Al- | | | | | | |
| Adha, which ser | ve to mitigate ou | utbreak risks. | | | | | | | | | |

| Middle Eastern Respiratory Syndrome Coronavirus (MERS-CoV) | | | | | | | | | | |
|--|--------------------|-------------------|-------------------|------------------|-------------------|--|--|--|--|--|
| Negligible | Very Low | Low | Moderate | High | Critical | | | | | |
| Gulf CDC Risk A | ssessment of this | Hazard | | | | | | | | |
| The majority of | MERS-CoV infect | ions to date have | e occurred due to | exposure to dro | medary camels. | | | | | |
| Nevertheless, h | uman-to-human | transmission of I | MERS-CoV can oc | cur among close | contacts and in | | | | | |
| healthcare sett | ings. The likeliho | od of a case b | eing imported in | ito Saudi Arabia | is "negligible". | | | | | |
| However, there | e is a slight char | ce of an interna | al pilgrim being | infectious and p | performing Hajj. | | | | | |
| Nevertheless, t | the human-to-hu | man sustained | transmission of | MERS-CoV has | not previously | | | | | |
| occurred, so despite its respiratory nature, it is "unlikely" to spread during Hajj mass gatherings. | | | | | | | | | | |
| However, robu | st public health s | urveillance in Sa | udi Arabia and tł | ne GCC countries | s are in place to | | | | | |
| identify and iso | late cases rapidly | | | | | | | | | |





| Yellow Fever | | | | | | | | |
|--|-------------------------------|-------------------------------|-------------------|-------------------|-------------------|--|--|--|
| Negligible | Very Low | Low | Moderate | High | Critical | | | |
| Gulf CDC Risk A | ssessment of this | Hazard | | | | | | |
| Yellow fever is a | a mosquito-borne | e disease conside | red to have a sev | ere pathogen sev | verity. The case- | | | |
| fatality rate for | severe cases is 3 | 30%–60% ⁽¹⁶⁾ . The | ere are no approv | ved treatments f | or yellow fever. | | | |
| Saudi Arabia h | as mandated th | e presentation | of a yellow feve | r vaccination ce | ertificate during | | | |
| applications for | [.] Hajj visas/permi | ts for individuals | traveling from co | ountries or areas | at risk of yellow | | | |
| fever transmiss | ion (See Appendi | x D). However, G | GCC nationals and | long-term reside | ents may not be | | | |
| routinely vaccinated, which could slightly increase the chance of importation. While the Aedes | | | | | | | | |
| <i>aegypti</i> mosquito is present in the GCC, the virus itself is not circulating. Strong public health | | | | | | | | |
| measures are ir | n place in all cour | tries to effective | ly manage any im | ported case. | | | | |

(c) Level of Confidence

The level of confidence in the assessment is **moderate**. The available data provide a reasonable basis for assessment. However, estimates have been produced by a mathematical model based on assumed parameters and do not accurately reflect the situation. Any estimates and their interpretation should be considered with caution.





V. Recommendations to GCC Countries

- 1. Review national policies for the vaccination of Hajj pilgrims and consider mandating COVID-19, influenza, and meningococcal vaccinations for all pilgrims.
- 2. Request Hajj clinics to ensure the validity of pilgrim's (1-year-old and above) meningococcal vaccination certificates and appropriate vaccination type and timing (including clear dates) as follows:
 - a. Quadrivalent (ACYW) Polysaccharide Vaccine, 10 days prior to arrival and should not exceed 3 years.
 - b. Quadrivalent (ACYW) Conjugated Vaccine within the last 5 years and at least 10 days prior to arrival.
- 3. Enhance Gulf CDC and GCC-national epidemic intelligence activities with a focus on Hajj zones (Makkah, Jeddah, Madinah, Taif) and languages spoken by pilgrims from the top ten countries.
- 4. Conduct a national risk assessment to identify any additional measures to be taken based on national needs.
- 5. Increase risk communication activities, particularly at travel clinics and Hajj centers, to raise pilgrim's awareness before coming to Hajj regarding personal protective measures against the high-priority diseases identified (e.g. hygiene, mask use, choosing a suitable barber, etc.).
- 6. Review screening measures at points of entry and exit (in all GCC countries for Hajj pilgrims) and conduct refresher training of staff, particularly on the high-priority disease.
- 7. Consider implementing enhanced screening measures for high-priority diseases identified from at-risk-countries for individuals transiting through major airports
- 8. Raise awareness of high-priority diseases identified for Hajj via regular communications (e.g. circulars) to all relevant public health professionals, particularly clinicians.
- 9. Enhance surveillance and laboratory capacities for early detection of any infectious disease with a focus on Hajj.
- 10. Enhance vector surveillance and vector control programs and activities for vectorborne diseases.
- 11. Enhance preparedness and readiness measures for necessary medicines, supplies, and health awareness materials and tools.
- 12. Consider enforcement of vaccination and other public health measures for Hajj pilgrims, as set per Saudi Guidelines (see example in Appendix E).





VI. References

1. Hajj statistics 2023-1444. General authority for statistics [Internet]. [cited 2024 May 15]. Available from: <u>https://www.stats.gov.sa/system/tdf/file_manger/Hajj%20Report%201444H-</u> EN_compressed-2.pdf?file=1&type=node&id=145224&force=0

2. GASTAT announces the total number of Umrah performers and pilgrims for 1443 /2022. General authority for statistics [Internet]. [cited 2024 May 15]. Available from: <u>https://www.stats.gov.sa/en/news/463</u>

3. Aldossari M, Aljoudi A, Celentano D. Health issues in the Hajj pilgrimage: a literature review. East Mediterr Health J [Internet]. 2019 [cited 2024 May 15];25(10). Available from: http://dx.doi.org/10.26719/2019.25.10.744

4. Pilgrim's health [Internet]. Ministry Of Health Saudi Arabia. [cited 2024 May 15]. Available from: <u>https://www.moh.gov.sa/en/HealthAwareness/Pilgrims_Health/Pages/respiratory-infection.aspx</u>

5. Saber Yezli, Yara Yassin, Abdulaziz Mushi, Alhanouf Aburas, Lamis Alabdullatif, Mariyyah Alburayh, et.al: Gastrointestinal symptoms and knowledge and practice of pilgrims regarding food and water safety during the 2019 Hajj mass gathering. BMC Public Health, [Internet]. 2021 Jul 1 [cited 2024 May 15]; 21(1). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8252316/

6. Saudi Arabia: Hajj & umrah pilgrimages. CDC [Internet]. [cited 2024 May 19]. Available from: <u>https://wwwnc.cdc.gov/travel/yellowbook/2024/itineraries/saudi-arabia-hajj-and-umrah-pilgrimages</u>

7. Zumla A, McCloskey B, Endericks T, Azhar EI, Petersen E. The challenges of cholera at the 2017 Hajj pilgrimage. Lancet Infect Dis [Internet]. 2017 [cited 2024 May 19];17(9):895–7. Available from: http://dx.doi.org/10.1016/s1473-3099(17)30454-1

8.من 1997م. [cited 2024 May] بالفيديو.اللواء متقاعد منصور التركي يتحدث عن تفاصيل حريق منى 1997م. 22]. Available from: <u>https://slaati.com/2020/04/26/p1640528.html</u>

9.١٤٤٤-٢٠٢٣ الدليل الإرشادي للإجراءات الوقائية للأمراض المعدية ذات الأهمية خلال موسم الحج. [cited 2024 May 23]. Available from: <u>https://www.moh.gov.sa/CCC/healthp/regulations/Documents/Guidelines-for-Preventive-</u> Measures-Infectious-diseases-during-Haji-1444H-2023.pdf

10. Meningococcal Disease. CDC [Internet]. [cited 2024 May 15]. Available from: <u>https://www.cdc.gov/meningococcal/about/index.html</u>

11. Health Requirements and Recommendations for Travelers to Saudi Arabia for Hajj – 1445H (2024). Ministry of Health [Internet]. [cited 2024 May 15]. Available from: <u>https://www.moh.gov.sa/HealthAwareness/Pilgrims_Health/Documents/Hajj-Health-Requirements-English-language.pdf</u>

12. Hajj 1432 - Influenza and the Hajj [Internet]. [cited 2024 May 23]. Available from: https://www.moh.gov.sa/en/Hajj1432/Pages/Influenza-and-the-Hajj.aspx

13. Shetty S, Murmann M, Tuite AR, Watts AG, Bogoch I, Khan K. Measles and the 2019 Hajj: risk of international transmission. J Travel Med [Internet]. 2019 Sep 2 [cited 2024 May





29];26(6):1–2. Available from: https://academic.oup.com/jtm/article/26/6/taz058/5549356?login=false

14. D K Karaolis, R Lan, and P R Reeves. The sixth and seventh cholera pandemics are due to independent clones separately derived from environmental, nontoxigenic, non-O1 Vibrio cholerae. Journal of bacteriology [Internet]. 1995 Jun [cited 2024 June 9]; 177(11): 3191–3198. Available from: https://doi.org/10.1128%2Fjb.177.11.3191-3198.1995

15. 50 cases of Crimean-Congo hemorrhagic fever in Iraq: KRG Minister of Health [Internet]. [cited 2024 June 4]. Available from: <u>https://www.kurdistan24.net/en/story/35032-50-</u> cases-of-Crimean-Congo-hemorrhagic-fever-in-Iraq:-KRG-Minister-of-Health

16. Yellow fever. CDC [Internet]. [cited 2024 June 4]. Available from: https://wwwnc.cdc.gov/travel/yellowbook/2024/infections-diseases/yellow-fever






VII. Appendices

Appendix A: Importation likelihood ratios of Infectious diseases in the top 10 countries with the most Hajj visas granted and where the highest number of pilgrims is expected to come from.

Table 1. Average Importation Likelihood of Active Infectious Diseases (BlueDot, 2024) in the potential Top 10 origin/Countries of most pilgrims for 2024.







| Likelihood | Impact | | | | | | |
|---------------------|------------|------------|------------|------------|------------|--|--|
| Likelinood | Negligible | Minor | Moderate | Major | Severe | | |
| Negligible | Negligible | Negligible | Negligible | Negligible | Negligible | | |
| Unlikely | Negligible | VERY LOW | LOW | LOW | MODERATE | | |
| Likely | Negligible | LOW | LOW | MODERATE | MODERATE | | |
| Highly likely | Negligible | LOW | MODERATE | MODERATE | HIGH | | |
| Almost certain/sure | Negligible | MODERATE | MODERATE | HIGH | CRITICAL | | |

Appendix B: Gulf CDC Risk Characterization Matrix

Appendix C: Countries/areas with frequent epidemics of meningococcal meningitis and countries at risk for meningitis epidemics (WHO International Travel and Health, 2015):

| | Africa | |
|-------------|---------------|--------------------------|
| Nigeria | Ethiopia | Burkina Faso |
| South Sudan | Gambia | Burundi |
| Rwanda | Ghana | Cameroon |
| Senegal | Guinea | Central African Republic |
| Sudan | Guinea-Bissau | Chad |
| Tanzania | Kenya | Côte d'Ivoire |
| Тодо | Mali | DR Congo |
| Uganda | Mauritania | Eritrea |
| Niger | Benin | |

Appendix D: Countries/areas at risk of Yellow Fever transmission, as per the WHO International Travel and Health Guidelines, are:

| Ame | erica | Afı | rica |
|----------|---------------------|---------------|--------------------------|
| Guyana | Argentina | Ghana | Angola |
| Panama | Venezuela | Guinea | Benin |
| Paraguay | Bolivia | Guinea-Bissau | Burkina Faso |
| Peru | Brazil | Kenya | Burundi |
| Surinam | Colombia | Liberia | Cameroon |
| Ecuador | Trinidad and Tobago | Mali | Central African Republic |
| | French Guiana | Mauritania | Chad |
| | | Niger | Congo |
| | | Nigeria | Côte d'Ivoire |
| | | Senegal | DR Congo |
| | | Sierra Leone | Equatorial Guinea |
| | | Sudan | Ethiopia |
| | | Gambia | Gabon |
| | | Тодо | South Sudan |
| | | Uganda | |





Appendix E: Vaccines required for intenal and external pilgrims (Saudi Ministry of Health 2024/1445)

| histry of Health | ت اج الداغل | <mark>نے ج</mark> | تد |
|---|---|--|-------------------------------|
| فيــــروس ڪورونا–19 | الإنفلونــزا الموسمية | الحمى الشوكية النيسيريـــــــة | التطعيم |
| لم يتلقوا اللقاح ذــــــلال عــــام 1445هـ | لم يتلقوا اللقاح خــــــلال عــــام 1445هـ | لم يتلقوا اللقاح خلال الخمــــس سنوات الماضية | م ⁵ م لمـــن |
| بل الحــج | ت من الآن وحتى 10 أيـام ق | تتاح التطعيمـــان | متــــى |
| بيق صحتي | عيادة لقاحات الحج عبر تط | احجز موعدك في | |
| | ناج الخارج | لحج | |
| شــــلل الأطفال | الحمـــــى الصفــراء | الحمى الشوكية النيسيريــــــة | التطعيم |
| للقادمين من الدول التي يسـري فيهــا شلل الأطفال | للقادمين من الدول التي يسـري فيهــا الحمي الصفراء | لم يتلقوا اللقـــاح خلال 3 أو 5 سنـوات الماضية حسب نوع التطعيم | مي ⁷ م لمــــن |
| لا تقل عن 4 أسابيع ولا تزيـد عن سنــة | ام قبـــــل الحـــج | حتـــى 10 أيـــــــــ | متــــى |
| ىمية بجرعة أُعطيت خلال قاً للاشتراطات الصحية | ورونا - 19 والانفلونزا الموس د الأمراض المستهدفة وف | ال التحصين ضد فيروس ك لى جانب تحديث التحصين ض | یوصی باستکم عام 1445 هـ إا |
| moh.gov.sa | % 937 ∉∂`X⊡© | SaudiMOH 🔱 Sau | ıdi_Moh |





VIII. Acknowledgments

The Gulf CDC is thankful to BlueDot for providing the likelihood ratios of importing some diseases during Hajj.

IX. Authors

Developed by:

Naif Alharbi, Lubna Al Ariqi, Leena Almohsen, Leena Zeyad, Fay Al Ghimlas

Reviewed and validated by:

Gulf Public Health Emergencies Network:

(Members in alphabetical order: Adel Al Sayyad, Afaf Merza, Amina Al Jardani, Amjad Ghanem, Aisha Alshaaili, Emad El Mohammadi, Fatima Alalkeem, Fatma Al Attar, Ghada Alzayani, Hamad Bastaki, Hamad Alromaihi, Khalid AlHarthy, Shk. Mohammed Hamad Al-Thani, Nada Almarzouqi, Sabria Al-Marshudi, Sarah Alqabandi, Soha Albayat, Sondos Alqabandi)

Gulf CDC:

Sami Almudarra, Abdulaziz Alzayed, Rasha Alfawaz, Katrin Leitmeyer, Pasi Penttinen